- Conditions
- Leukemia
- Interventions
- filgrastim, recombinant interferon alfa, busulfan, cytarabine, etoposide, hydroxyurea, idarubicin, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • Red Bank, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 2,507
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy
- Drug · Procedure
- Lead sponsor
- Nathan Wei, MD, FACP, FACR:
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Frederick, Maryland
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 3 more
- Conditions
- Osteopetrosis
- Interventions
- Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
- Procedure · Device · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Brain Metastases
- Interventions
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, CD70 IHC assay
- Biological · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2044
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Hypoglycemia, Type 1 Diabetes
- Interventions
- Saline, C-peptide
- Other · Biological
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Breast Cancer
- Interventions
- [11C]Martinostat, MR-PET scanner
- Drug · Device
- Lead sponsor
- Christine Elizabeth Edmonds
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hematologic Malignancy
- Interventions
- melphalan, fludarabine, thiotepa, Cyclophosphamide, Mesna, Mycophenolate Mofetil, Filgrastim, Tacrolimus
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myoma
- Interventions
- Vasopressins
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2015
- U.S. locations
- 2
- States / cities
- Beachwood, Ohio • Cleveland, Ohio
- Conditions
- Lymphoma, Neutropenia
- Interventions
- filgrastim, pegfilgrastim, cisplatin, cytarabine, etoposide, methylprednisolone
- Biological · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Omaha, Nebraska • Cleveland, Ohio
- Conditions
- Friedreich Ataxia, Healthy Volunteers
- Interventions
- Buccal Swabs, Blood Draws and Skin Punch Biopsy
- Diagnostic Test
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Cesarean Section Complications, Wound Breakdown, Wound Infection, Satisfaction, Surgical Wound Infection
- Interventions
- ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG), Standard Wound Care
- Combination Product · Other
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Congestive Heart Failure, Cardiorenal Syndrome
- Interventions
- nesiritide, placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Blood Loss, Surgical, Postpartum Hemorrhage, Bleed Pregnancy, Pregnancy Related, Cesarean Section Complications
- Interventions
- Oxytocin, Placebo
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Lymphoma
- Interventions
- aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
- Biological · Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
- Conditions
- Leukemia
- Interventions
- Talazoparib, Decitabine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Retinitis Pigmentosa
- Interventions
- NT-501
- Drug
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Hypertension
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Weight Loss, Starvation
- Interventions
- Caloric Restriction, Protein, Exercise, Calcium and Vitamin D, Maltodextrin
- Other · Dietary Supplement
- Lead sponsor
- University of Nebraska Lincoln
- Other
- Eligibility
- 19 Years to 30 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Melanoma
- Interventions
- Fibrin Sealant
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- IPF
- Interventions
- Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
- Drug
- Lead sponsor
- Michael Donahoe
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- Bicalutamide, Flutamide, Goserelin Acetate, Ipilimumab, Leuprolide Acetate, Pharmacological Study
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Sclerosis
- Interventions
- Tysabri
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York